Characterizes insulin exposure and glucose control in individuals with type 2 diabetes, indicating effective management over time.
Efsitora demonstrated a flat, prolonged PK profile, providing a consistent level of insulin exposure at steady-state and resulting in a stable glucose-lowering response across the weekly dosing interval.
No takes yet. Share an insight, caveat, or question.
Leohr et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: